Clinical Trials
62 trialsMK-5684-004
Merck Sharp & Dohme LLC
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Telix Pharmaceuticals (Innovations) Pty Limited
MK-2400-001
Merck Sharp & Dohme LLC
A Study of Changes to Prostate Procedures
Memorial Sloan Kettering Cancer Center
MEVPRO-3
Pfizer
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Amgen
ROPES
Brigham and Women's Hospital
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
M.D. Anderson Cancer Center
EvoPAR-PR02
AstraZeneca
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Eastern Cooperative Oncology Group
CLARIFY
Clarity Pharmaceuticals Ltd
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Alliance for Clinical Trials in Oncology
Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
NRG Oncology
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NRG Oncology
PEACE-4
Gustave Roussy, Cancer Campus, Grand Paris
rechARge
Celgene
OPTION-DDR
Canadian Cancer Trials Group
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
ABX advanced biochemical compounds GmbH
ASCENDE-SBRT
Canadian Cancer Trials Group
TRIPLE-SWITCH
Canadian Cancer Trials Group
Solar-Stage
Curium US LLC
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
University of Texas Southwestern Medical Center
Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer
Samsung Medical Center
PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer
Centre hospitalier de l'Université de Montréal (CHUM)
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
Emory University
AcTFirst
Novartis
Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer
Mayo Clinic
ID-COMET
Roswell Park Cancer Institute
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
SWOG Cancer Research Network
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Mayo Clinic
ViPER
University of Rochester
VORTEX
Jonsson Comprehensive Cancer Center
Apa/Enza-short
Erasmus Medical Center
18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028
University of Alberta
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
European Organisation for Research and Treatment of Cancer - EORTC
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
SWOG Cancer Research Network
BiPASS
Telix Pharmaceuticals (Innovations) Pty Limited
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
Proton Collaborative Group
GrandP/SPCG19
The Hospital of Vestfold
MOVES
Tampere University Hospital
PEACE 7
UNICANCER
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
University of Texas Southwestern Medical Center
ENFORCE
Canisius-Wilhelmina Hospital
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
Icahn School of Medicine at Mount Sinai
CREATINE-52
University of Utah
Comparing "Salvage" Radiotherapy and Individualized PSMA PET/CT Targeted Treatment in With Relapsing Prostate Cancer
Karolinska University Hospital
Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy
Ottawa Hospital Research Institute
Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation
Region Västerbotten
Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
HTA Co., Ltd.